Ballast小型/中型股主動型ETF MGMT 深 滬
已收盤 05-22 16:00:00 美东时间
47.60
+0.420
+0.89%
華盛通- 最 高47.645
- 今 開47.56
- 成交量 4.70万股
- 最 低 47.22
- 昨 收 47.18
- 總市值 1.71亿
- 52周最高 50.23
- 市盈率 靜 --
- 換手率 1.30%
- 52周最低 37.7437
- 委 比 0.00%
- 總股本 359.97万
- 歷史最高 50.23
- 量 比 6.87
- 振 幅 0.90%
- 歷史最低 24.1332
- 每 手 1
- 風險率 3.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Caris study validates AI signature predicting temozolomide benefit in glioblastoma patients
Caris study validates AI signature predicting temozolomide benefit in glioblastoma patients Caris Life Sciences published peer-reviewed validation results in Neuro-Oncology Advances for an AI-derived signature intended to guide temozolomide use in glioblastoma. Study found signature aligned with sta
04-29 20:48
GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates
GEO Group reported lower Q1 revenue and adjusted EBITDA, missing consensus. EPS also fell short. Outlook raised for FY25 but Q2 expectations lowered.
2025-05-07 23:32
Shuttle Pharmaceuticals Expands Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma Treatment
Shuttle Pharmaceuticals Holdings Inc. has announced an update to its clinical trial for the drug Ropidoxuridine, a radiation sensitizing agent. The company has entered into a change order with Therade...
2025-01-29 05:11
AZZ Eyes Growth Spurt: Strong Markets Fuel FY25 Sales, Profit Forecast
AZZ raises FY25 guidance due to strength in several end markets. Sales outlook increased to $1.525-$1.625B, adjusted EPS to $4.50-$5.00, and adjusted EBITDA to $310-$360M. Company plans to report Q4 results on April 22, 2024.
2024-04-08 20:43
